Posters

The effects of an innovative lubricating ophthalmic solution in minimizing dry eye disease associated to cataract surgery. The results of a multicenter, randomized, prospective study

Poster Details

First Author: P.Fogagnolo ITALY

Co Author(s):    E. Favuzza   L. Rossetti   M. Cennamo   D. Marchina   C. Quisisana   R. Mencucci     

Abstract Details

Purpose:

To evaluate the effects of a new lubricating, antioxidant solution (VisuEvo®) on dry eye disease (DED) in patients undergoing cataract surgery

Setting:

Eye Clinics of Careggi Hospital, University of Florence (Italy) and of San Paolo Hospital - ASST Santi Paolo e Carlo of Milan, University of Milan, Italy

Methods:

Patients requiring cataract surgery with either healthy ocular surface or mild DED (tear break-up time, TBUT>7, Schirmer>15 mm/5 minutes) were enrolled in this multicenter, open-label, randomized, prospective study. Scheduled visits were 2 weeks before surgery (screening), day of surgery (V0), week 1 (V1), and 2 (V2) after surgery. VisuEvo® was self-administered three times daily for the whole study duration (group A); the control group (group B) had no tear substitute administration. Primary endpoint was the change in TBUT over time; secondary endpoints were changes in Ocular Surface Disease Index (OSDI), ocular surface staining, Schirmer I, and osmometry.

Results:

45 patients were included (group A, 23; group B, 22; age 74±8 years). At the screening, TBUT was similar among the groups (group A, 8.5±1.8 sec; group B, 7.8±0.7, p=0.11). At the scheduled visits, TBUT was significantly higher in group A: 1.2 sec at V0, 1.4 sec at V1, and 1.9 sec at V2 (p<0.01). Also OSDI was significantly lower in group A at V0, V1, and V2 (p<0.027). After surgery, corneal staining was absent in 65-78% of group A compared with 54-59% in group B. The two groups did not show any significant difference of osmometry and Schirmer I test.

Conclusions:

Compared to the natural course of DED after cataract surgery, the ocular surface was more protected and quickly restored from surgery when VisuEvo® was used from 2-week preoperatively to 2 weeks postoperatively.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company